Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P62988 (
Ubiquitin
)
4,326
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Ubiquitination of eukaryotic proteins regulates a broad range of cellular processes, including T cell activation and tolerance. We have previously demonstrated that
GRAIL
(
gene related to anergy in lymphocytes
), a transmembrane RING finger ubiquitin E3 ligase, initially described as induced during the induction of CD4 T cell anergy, is also expressed in resting CD4 T cells. In this study, we show that
GRAIL
can down-modulate the expression of CD83 (previously described as a cell surface marker for mature dendritic cells) on CD4 T cells.
GRAIL
-mediated down-modulation of CD83 is dependent on an intact
GRAIL
extracellular protease-associated domain and an enzymatically active cytosolic RING domain, and proceeds via the ubiquitin-dependent 26S proteosome pathway.
Ubiquitin
modification of lysine residues K168 and K183, but not K192, in the cytoplasmic domain of CD83 was shown to be necessary for
GRAIL
-mediated degradation of CD83. Reduced CD83 surface expression levels were seen both on anergized CD4 T cells and following
GRAIL
expression by retroviral transduction, whereas
GRAIL
knock-down by RNA interference in CD4 T cells resulted in elevated CD83 levels. Furthermore, CD83 expression on CD4 T cells contributes to T cell activation as a costimulatory molecule. This study supports the novel mechanism of ubiquitination by
GRAIL
, identifies CD83 as a substrate of
GRAIL
, and ascribes a role for CD83 in CD4 T cell activation.
...
PMID:The transmembrane E3 ligase GRAIL ubiquitinates and degrades CD83 on CD4 T cells. 1954 55